- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr. Joshua Bershad Describes the Robert Wood Johnson University Hospital's Community Care Initiative
Dr. Joshua Bershad, Senior Vice President, Medical Affairs and Chief Medical Officer,
, talks about the $4 million grant the hospital received from the Robert Wood Johnson Foundation to launch a Community Care Initiative, and how healthcare professionals across the nation can make the most of these changing times.
Robert Wood Johnson University Hospital, New Brunswick, NJ
In addition, Dr. Bershad discusses specific aspects of the Community Care Initiative, such as linking communities to Robert Wood Johnson University Hospital to lower hospital readmission rates. He also discusses the initiative's two-pronged approach: direct services, which involves the transitional care model to provide supportive systems for patients when they leave the hospital (eg, transitional care nurse to call and visit patients at their home to ensure medication adherence, proper diet, etc); and health information technology to tie the provider network together and increase communication/transfer of information.
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More
